X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://ir.sana.com/news-releases/news-release-details/sana-biotechnology-reports-fourth-quarter-and-full-year-2023
https://www.globenewswire.com//news-release/2024/02/28/2837405/0/en/Sana-Biotechnology-to-Present-at-the-Cowen-44th-Annual-Health-Care-Conference.html
https://www.fiercebiotech.com/research/sanas-engineered-pancreatic-islet-cells-control-blood-sugar-monkey-model-type-1-diabetes
https://www.globenewswire.com//news-release/2024/02/13/2828638/0/en/Sana-Biotechnology-Announces-Publication-of-Preclinical-Diabetes-Data-in-Cell-Stem-Cell-Demonstrating-Insulin-Independence-Following-Transplantation-of-Hypoimmune-Allogeneic-Primar.html
https://www.globenewswire.com//news-release/2024/02/12/2827865/0/en/Sana-Biotechnology-Announces-Closing-of-Upsized-Public-Offering-and-Full-Exercise-of-Underwriters-Option-to-Purchase-Additional-Shares.html
https://www.globenewswire.com//news-release/2024/02/08/2825690/0/en/Sana-Biotechnology-Announces-Pricing-of-Upsized-Public-Offering.html
https://www.globenewswire.com//news-release/2024/02/07/2825536/0/en/Sana-Biotechnology-Announces-Proposed-Public-Offering-of-Common-Stock.html
https://www.globenewswire.com//news-release/2024/01/05/2804686/0/en/Sana-Biotechnology-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-SC262-a-Hypoimmune-modified-CD22-directed-Allogeneic-CAR-T-Therapy-for-Patients-with-Relapsed.html
https://www.globenewswire.com//news-release/2024/01/03/2803609/0/en/Sana-Biotechnology-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html
https://www.globenewswire.com//news-release/2023/12/11/2793899/0/en/Sana-Biotechnology-Highlights-Preclinical-Data-Supporting-Tumor-Control-and-Immune-Evasion-Capabilities-of-Hypoimmune-Modified-Allogeneic-CAR-T-Cells-in-Presentations-at-the-Americ.html
Market Place
Share 
